{"denoms":[{"counts":[{"groupId":"BG000","value":"239"},{"groupId":"BG001","value":"242"},{"groupId":"BG002","value":"481"}],"units":"Participants"}],"groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"BG000","title":"Vincristine, Dactinomycin, Cyclophosphamide (VAC)"},{"description":"Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"BG001","title":"VAC Alternating With Vincristine, Irinotecan (VI)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"73.39","value":"89.85"},{"groupId":"BG001","spread":"82.66","value":"97.86"},{"groupId":"BG002","spread":"78.21","value":"93.88"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"222"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"259"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"67"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"191"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"395"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"66"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"346"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"51"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}